Overview Financials News + Filings Key Docs Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
OPIANT PHARMACEUTICALS, INC. (LLTP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/13/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 03/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/06/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/06/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/06/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/06/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/06/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/06/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/06/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/06/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/06/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/03/2023 |
4
| Silver Gabrielle Alison (Director) has filed a Form 4 on OPIANT PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 21,343 shares
@ $20, valued at
$426.9k
Disposed/sold 2,000 shares
@ $20, valued at
$40k
Disposed/sold 2,500 options to buy
@ $15.56, valued at
$38.9k
Disposed/sold 2,500 options to buy
@ $12.75, valued at
$31.9k
Disposed/sold 2,500 options to buy
@ $8.79, valued at
$22k
Disposed/sold 2,500 options to buy
@ $13.3, valued at
$33.3k
|
|
| 03/03/2023 |
4
| Collard Craig A (Director) has filed a Form 4 on OPIANT PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 53,822 shares
@ $20, valued at
$1.1M
Disposed/sold 2,000 shares
@ $20, valued at
$40k
Disposed/sold 5,000 options to buy
@ $17.61, valued at
$88.1k
Disposed/sold 2,500 options to buy
@ $12.75, valued at
$31.9k
Disposed/sold 2,500 options to buy
@ $8.79, valued at
$22k
Disposed/sold 2,500 options to buy
@ $13.3, valued at
$33.3k
|
|
| 03/03/2023 |
4
| Ruth Matthew R. (Chief Commercial Officer) has filed a Form 4 on OPIANT PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 19,250 shares
@ $20, valued at
$385k
Disposed/sold 10,666 shares
@ $20, valued at
$213.3k
Granted 2,000 shares
@ $0
Disposed/sold 2,000 shares
@ $20, valued at
$40k
Disposed/sold 50,000 options to buy
@ $16.41, valued at
$820.5k
|
|
| 03/03/2023 |
4
| Daly Richard J (Director) has filed a Form 4 on OPIANT PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 5,800 shares
@ $20, valued at
$116k
Disposed/sold 2,000 shares
@ $20, valued at
$40k
Disposed/sold 2,500 options to buy
@ $12.75, valued at
$31.9k
Disposed/sold 2,500 options to buy
@ $13.3, valued at
$33.3k
Disposed/sold 5,000 options to buy
@ $15.56, valued at
$77.8k
Disposed/sold 2,500 options to buy
@ $8.79, valued at
$22k
|
|
| 03/03/2023 |
4
| CRYSTAL ROGER (CEO) has filed a Form 4 on OPIANT PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 37,438 shares
@ $20, valued at
$748.8k
Disposed/sold 37,901 shares
@ $20, valued at
$758k
Disposed/sold 5,100 shares
@ $20, valued at
$102k
Granted 6,667 shares
@ $0
Disposed/sold 6,667 shares
@ $20, valued at
$133.3k
Disposed/sold 25,000 options
@ $6, valued at
$150k
Disposed/sold 150,000 options
@ $5, valued at
$750k
Disposed/sold 375,000 options
@ $7.25, valued at
$2.7M
Disposed/sold 13,200 options to buy
@ $14.62, valued at
$193k
Disposed/sold 27,250 options to buy
@ $13.6, valued at
$370.6k
Disposed/sold 31,250 options to buy
@ $12.15, valued at
$379.7k
|
|
| 03/03/2023 |
4
| Ellison Mark Jason Heath (Chief Development Officer) has filed a Form 4 on OPIANT PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 7,015 shares
@ $20, valued at
$140.3k
Disposed/sold 11,736 shares
@ $20, valued at
$234.7k
Disposed/sold 9,680 shares
@ $20, valued at
$193.6k
Granted 2,000 shares
@ $0
Disposed/sold 2,000 shares
@ $20, valued at
$40k
Disposed/sold 7,200 options to buy
@ $13.61, valued at
$98k
Disposed/sold 8,250 options to buy
@ $13.6, valued at
$112.2k
Disposed/sold 10,750 options to buy
@ $12.15, valued at
$130.6k
|
|
| 03/03/2023 |
4
| Skolnick Phil (Chief Scientific Officer) has filed a Form 4 on OPIANT PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 9,812 shares
@ $20, valued at
$196.2k
Disposed/sold 11,736 shares
@ $20, valued at
$234.7k
Granted 2,000 shares
@ $0
Disposed/sold 2,000 shares
@ $20, valued at
$40k
Disposed/sold 40,000 options to buy
@ $9, valued at
$360k
Disposed/sold 13,200 options to buy
@ $13.61, valued at
$179.7k
Disposed/sold 8,250 options to buy
@ $13.6, valued at
$112.2k
Disposed/sold 10,750 options to buy
@ $12.15, valued at
$130.6k
|
|
| 03/03/2023 |
4
| Sinclair Michael (10% Owner) has filed a Form 4 on OPIANT PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 27,450 shares
@ $20, valued at
$549k
Disposed/sold 22,720 shares
@ $20, valued at
$454.4k
Disposed/sold 40,000 shares
@ $20, valued at
$800k
Disposed/sold 100,000 options
@ $8, valued at
$800k
Disposed/sold 250,000 options
@ $7.25, valued at
$1.8M
Disposed/sold 75,000 options
@ $6, valued at
$450k
|
|
| 03/03/2023 |
4
| MacDougall Ann L. (Director) has filed a Form 4 on OPIANT PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 26,179 shares
@ $20, valued at
$523.6k
Disposed/sold 2,000 shares
@ $20, valued at
$40k
Disposed/sold 2,500 options to buy
@ $15.56, valued at
$38.9k
Disposed/sold 2,500 options to buy
@ $12.75, valued at
$31.9k
Disposed/sold 2,500 options to buy
@ $8.79, valued at
$22k
Disposed/sold 2,500 options to buy
@ $13.3, valued at
$33.3k
|
|
| 03/03/2023 |
4
| Lorianne Masuoka K. (Director) has filed a Form 4 on OPIANT PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 2,000 shares
@ $20, valued at
$40k
Granted 5,000 options to buy
@ $10.8, valued at
$54k
|
|
| 03/03/2023 |
4
| Gorman Brian (General Counsel) has filed a Form 4 on OPIANT PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 14,540 shares
@ $20, valued at
$290.8k
Disposed/sold 17,450 shares
@ $20, valued at
$349k
Granted 2,000 shares
@ $0
Disposed/sold 2,000 shares
@ $20, valued at
$40k
Disposed/sold 36,500 options to buy
@ $11.3, valued at
$412.5k
Disposed/sold 10,750 options to buy
@ $12.15, valued at
$130.6k
|
|
| 03/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2023 |
4
| O'Toole David D (CFO) has filed a Form 4 on OPIANT PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 22,512 shares
@ $20, valued at
$450.2k
Disposed/sold 11,736 shares
@ $20, valued at
$234.7k
Granted 2,000 shares
@ $0
Disposed/sold 2,000 shares
@ $20, valued at
$40k
Disposed/sold 33,000 options to buy
@ $13.61, valued at
$449.1k
Disposed/sold 8,250 options to buy
@ $13.6, valued at
$112.2k
Disposed/sold 10,750 options to buy
@ $12.15, valued at
$130.6k
|
|
| 03/02/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 03/02/2023 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa... |
| 03/01/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 02/27/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/22/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 02/07/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 02/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/06/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
|
|
|